SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.
The agent also exhibited a manageable safety profile.
“This is the first study to report a third-generation HER2-directed antibody-drug conjugate in the neoadjuvant treatment of HER2-positive breast cancer,” Jun-Jie Li, MD, of Fudan University Shanghai Cancer Center, said during a presentation. “SHR-A1811 monotherapy is highly efficient